New Leaf Venture Partners is a leading healthcare technology investor, managing approximately $1 billion in funds, and investments in 49 companies. We focus on 3 sectors: biopharmaceuticals, medical devices, and information convergence. Our goal is to build strong companies by supporting exceptional teams in the development of clinically important and commercially attractive products.

Across all sectors and stages, our investment decisions are primarily driven by a fundamental assessment of the risks in the underlying development programs (i.e., technical, clinical, regulatory, and commercial risks). Before making an investment, we work with the management teams to identify key milestones that must be met to reach points of meaningful value inflection, and we ensure that adequate resources are provided for the company to achieve those milestones.

The NLV investment team has deep operating experience and medical and technical expertise which are integral to our active investment approach. This allows us to work closely with founders, management, and co-investors to identify and execute on a capital efficient and optimal path to value creation and exit. This focused and fundamentals driven investment approach generates attractive returns for our investors.

NLV Partners has offices in New York and Menlo Park, California. We are currently making new investments through New Leaf Ventures II, a $450 million fund, which started its investing cycle in mid-2008.

Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia

Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD

Chimerix Announces Pricing of Initial Public Offering

Durata Therapeutics Closes Public Offering of Common Stock

MEI Pharma’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model